Vice President, Human Metabolome Technologies
The importance of human microbiome research is rapidly gaining momentum for understanding its role in human health and disease. Our goal for this mini-symposium is to highlight the emerging microbiome areas of today: Technologies, Nutritionals and Therapeutics.
We will introduce you to HMT’s pivotal technology, Capillary Electrophoresis Mass Spectrometry: uniquely designed to support microbiome research. HMT’s services are comprised of different platforms designed to work with both pre-clinical and clinical studies and all sample types.
HMT is devoted to research excellence and innovation and we are excited to host this mini-symposium.
Date: 13th January 2021
Start Time: New York 13:00 | London 18:00 | Paris 19:00 |Singapore 02:00 (14 Jan) | Tokyo 03:00 (14 Jan) | Sydney 05:00 (14 Jan)
Duration: 1 hour 40minutes
Event Structure: 3 presentations &30-minute Q&A
Registration fee: Complimentary access
Webinar on-demand: Available to view until midnight 27 January 2021 (registration is required)
Human microbiome research is rapidly gaining momentum for its role in understanding human health and disease. While probiotics has been an important first step, the importance of understanding the influence of our microbiome on health and well-being continues to grow, linking the microbiome to disease development, progression, and outcomes. Metabolomics has become an increasingly important part in deciphering the role of the microbiota on human health, as more and more bacterial specific metabolites are discovered and new technologies are developed. Enabling technologies, such as Capillary Electrophoresis Mass Spectrometry, are at the leading edge of microbiome research due to the ability to identify and measure small, polar, and bacteria-specific metabolites. Along with Capillary Electrophoresis Mass Spectrometry, Alex will describe the advancements in metabolomic measurements as it relates to bacterial signalling and biochemical processing.
Alexander M. Buko
Human Metabolome Technologies
Animal models of Alzheimer’s disease (AD) recapitulate the severe amyloidosis and neuroinflammation that is evident in the human disease. We have tested the hypothesis that the composition of the intestinal microbiome plays a key role in modulating neuro-inflammation that will ultimately influence amyloid deposition in two established mouse models of A-beta-amyloidosis. We orally administered a combination of antibiotics to induce rapid and sustained alterations in gut microbial populations and our studies indicate that alterations in the microbiome parallel changes in plasma cytokines and chemokines, reductions in amyloid deposition and modulation of morphological and transcriptional landscapes of microglia. These effects are unique to male, but not female animals.
Thomas Reynolds Sr. Family Professor of Neuroscience and Director of the Center for Molecular Neurobiology
University of Chicago
Allergic disorders have dramatically increased in prevalence over the past decade, particularly in developed countries, and primary prevention of allergic disease has proved an elusive goal. There is growing evidence that the gut microbiome influences the development of wheezing and childhood asthma. Probiotics are increasingly considered as a promising treatment for the correction of dysbiosis, reduction of systemic inflammation, and modulation of allergic diseases. Metabolite production by bacteria has recently been implicated in the differentiation of peripherally induced regulatory T cells to suppress allergic disease. The aim of this study was to evaluate the efficacy of Bifidobacterium breve B632 (DSM 24706) and Ligilactobacillus (formerly Lactobacillus) salivarius LS01 (DSM 22775) in the prevention of allergic asthma attacks in a pediatric population. A total of 422 children (aged 3-14 years) were enrolled in a randomized, double-blind, placebo-controlled trial and assigned to two treatment groups: 212 subjects treated with probiotics and 210 subjects in the placebo group. Subjects were instructed to take an active or placebo sachet twice daily for eight weeks, and subsequent intake of one sachet daily for a further eight weeks. Children receiving placebo were significantly more likely to experience at least one respiratory episode during the treatment phase (n = 49 (23.3%), OR = 3.1, 95% CI 1.8-5.6) than those receiving probiotics (n = 19 (9.0%)). These strains may serve as a valid early-life pediatric intervention to prevent the development of asthmatic allergies and decrease severity of reactions. Ongoing clinical trials will analyze the role of microbially-derived metabolites in the effective reduction of respiratory episodes after treatment with probiotics.
Director of R&D, Seed Health
• Understanding the impact of skincare products on the microbiome and sensitive skin.
• Developing a new way to develop cosmetics to respect the skin microbiome and skin barrier function.
• Building an in vitro and in vivo microbiome platform to assess the impact of cosmetics on the skin microbiome.
Founder & CEO
Dr. Elsa Jungman skincare
Meet the speakers
Thomas Reynolds Sr. Family Professor of Neurosciences and Director, Center for Molecular Neurobiology, University of Chicago
Alex has been at the forefront of proteomics and metabolomics since his graduate work from 1975 to 1980 at the University of Virginia with Professor Don Hunt. After 4 years at the Bureau of Biologics and Biophysics at the FDA, Alex spent 28 years leading analytical chemistry and transitional medicine labs at Abbott and Biogen, working on such projects as the identification of novel antibiotics and the influence of the microbiome on disease progression in Multiple Sclerosis. Since 2013 Alex has been working at Human Metabolome Technologies, collaborating with clients performing different levels of microbiome related research: from basic understanding of bacterial signaling to the development of nutriceuticals and pharmaceuticals to address clinical needs and disease treatments.
Dr. Sisodia’s research has focused on understanding the cellular and molecular biology of the amyloid precursor protein (APP) and presenilins (PS1 and PS2), polypeptides that are mutated in pedigrees with familial Alzheimer’s Disease (FAD). His most notable contributions include the generation and characterization of mouse models that exhibit amyloid plaques in the brain. These models have been invaluable for understanding the impact of environmental enrichment and exercise in modulating amyloid deposition and adult neurogenesis. More recent studies have focused on the impact of the microbiome on modulation of Abeta amyloidosis in mouse models. He has published 185 peer-reviewed manuscripts.
Dr. Sisodia has received several awards, including: the Potamkin Prize for Alzheimer’s Disease Research from the American Academy of Neurology and the Metropolitan Life Foundation Award for Medical Research. He was inducted as a Fellow of AAAS, and Foreign Fellow of the National Academy of Sciences, India and the Spanish Royal Academy of Sciences. Dr.Sisodia has served on the Editorial Boards of eight journals, including Neuron and Cell, and is a member of the Dana Alliance for Brain Initiatives.
Dr. Gadir is the Director of R+D at Seed Health, a microbial sciences company pioneering applications of bacteria to impact human and environmental health. Dr. Gadir completed her postdoctoral training in the laboratory of Professor Talal Chatila at Harvard Medical School/Boston Children’s Hospital, where her published research was focused on the immunological mechanisms that underlie the role of the gut microbiome in conferring protection to diseases early in life. For this work, she holds issued and pending patents and has collaborated with industry partners to accelerate the discovery of microbiome-related immunotherapies for food allergy.
Mark Zbinden is a biochemist and educator, and the newest member of HMT. While his thesis work was in molecular neuroscience, he has a diverse scientific background: from artificial bilayer networks to bacterial protein characterization to the impact of lipid maturation in yeast metabolism. Utilizing his passion for education, Dr. Zbinden connects with clients and aids in experimental design, troubleshooting, and data interpretation.
Elsa Jungman, Ph.D., is a skin scientist and entrepreneur. She has a doctorate in skin delivery and began her career working in R&D for L’Oreal in Paris. In 2015 she moved to San Francisco and worked with several biotech and beauty companies. Her startup, Dr. Elsa Jungman (ELSI Skin health Inc), helps women connect with their skin by offering clean & personalized skincare with a specific focus on the microbiome. Dr Elsa Jungman is the first certified microbiome-friendly brand in the US. She was awarded the French-American Entrepreneurship award and is the editor of the new edition of “Handbook of Cosmetics Science & Technology”